The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical science"
DOI: 10.1042/cs20220447
Abstract: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have proven to delay diabetic kidney disease (DKD) progression on top of the standard of care with the renin-angiotensin system (RAS) blockade. The molecular mechanisms underlying the synergistic effect of… read more here.
Keywords: top ras; empagliflozin; map17 regulated; ras blockade ... See more keywords